ROARABLE
Today ⌘ Pro Terminal Big Ideas 🎲 Predictions Screener 🦋 Butterfly 8 Analysts 🏛️ Policy 🎬 Video ★ Watchlist 🎲 Prediction Markets 📊 RQD Track Record 📅 Next Catalysts 🛡️ Overlap & Crash X-Ray 📰 Live Wire 🐋 13F Whales 🏛️ Congress & CEO Buys 🏆 $100K Arena ⌘ Pro Terminal 📐 Methodology & Corrections
Stock Ratings / Health Care / SNDX / forecast
SLN (44) RAPP (30) OPK (40) VSTM (36) ⌘ Pro Terminal →

Syndax Pharmaceuticals Inc. (SNDX) 12-Month Stock Forecast & Price Target Cone

$13.10 -4.03% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $12.98

Syndax Pharmaceuticals Inc. (SNDX) carries a Roarable Rating of E (Strong Sell) with 17/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (17/100 · E) historically underperformed SPY in 71% of rolling 90-day windows →
ROARABLE E • RED ALERT Cap $1.22B
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on SNDX Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is SNDX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Syndax Pharmaceuticals Inc. (NASDAQ: SNDX) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 17/100 at a spot price of $13.10 (-4.03% 1D, market cap $1.22B). Pillar breakdown: Fundamental Cash Engine 3/20, Institutional 13F & Options Flow 4/20, Executive Insider Alignment 5/20, FRED Macro Regime Fit 5/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, SNDX ranks #1006 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does SNDX compare to SLN and RAPP in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), SNDX carries a Roarable E (17/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, SLN (Silence Therapeutics Plc American Depository Share) holds a D grade (44/100 RQD, P/E N/A, ROIC -35.0%, cap $1.23B) and RAPP (Rapport Therapeutics Inc.) posts a E grade (30/100 RQD, P/E N/A, ROIC -22.9%, cap $1.20B). Among the 5-stock peer group, SNDX leads on earnings multiple (N/A) while OPK leads on capital efficiency (-10.2% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for SNDX?
▼

Per SNDX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001395937), Syndax Pharmaceuticals Inc. generated $172.4M in revenue (+627.8% YoY), -$285.4M in net income, and -$323.2M in free cash flow against $529.7M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $12.98 (-0.92%)🧬 Dilution Drag (+1.28% YoY Shares)⚙️ Cash Engine: 3/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (17/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-12.5% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERRED ALERT • E
025507510017
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk E
Cash (3)Whales (4)SEC (5)Macro (5)CEO (3)
Each axis scored 0–20
12M PRICE TARGET CONE-18.5% Base Target
$27 Bull$11 Base$8 Bear
📬 FREE SNDX RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for SNDX)Realized 20D OHLCV Swing Band: ±9.9%
Deterministic 5-Pillar Attribution (17/100 Composite)
🔍 WHY SNDX SCORES 17/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+5/20 pts (29% of score)

Altman Z-Score 0.20 (DISTRESS RISK (<1.8)) • Piotroski F-Score 3/9

▲ #2 Bullish Driver: Macro Regime Fit+5/20 pts (29% of score)

FRED Regime × Technicals: 2% of 52W Range • RSI-14 at 37.8 (NEUTRAL RANGE)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+1.28% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
25
Grade E$13.95-5% Next Q
Q2 (-2Q)
22
Grade E$13.25+3.3% Next Q
Q3 (-1Q)
20
Grade E$13.69-4.3% Next Q
Current
17
Grade E$13.10-12.5% Hist 90D α
Trajectory: E (25) → E (17)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a SNDX Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While SNDX currently carries a cautious 17/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($16.95) and Max Pain ($13.76) forces dealer call-delta covering toward $26.87.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.28% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $SNDX• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “SNDX Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 18%NO 82%Trade / Inspect Odds →
INTERACTIVE 12-MONTH POSITION SIMULATOR

Drag to Test Your SNDX Position Size: $10,000

Shares at $13.10: 763.4 sh
$1,000$10,000$25,000$50,000$100,000
12M Bear Case FloorTarget $8.33
$6,359
$-3,641 (-36.4%)
12M Consensus BaseTarget $10.68
$8,153
$-1,847 (-18.5%)
12M Bull Case BreakoutTarget $26.87
$20,511
+$10,511 (+105.1%)

Wall Street Analyst Breakdown & Historical Accuracy Audit (35 Desks)

Street Historical Accuracy: 64/100
● Strong Buy / Buy: 17● Hold: 9● Sell: 9
Wall Street FirmStance12M Target1Y AccuracyTrack Grade
Morgan StanleyInstitutional Equity DeskHOLD$1174%A
Goldman SachsSector Coverage LeadUNDERPERFORM$2569%B
JP MorganUS Large-Cap ResearchSELL$1058%C
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring SNDX)

  • ✓Walkthrough of SNDX's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
SNDX // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -34.37%▼ DESCENDING CHANNEL
2026-11-03O $14.15H $14.15L $13.10C $13.10VOL 2.54M
RES: $16.86SUP: $11.87SMA50: $16.95SMA200: $20.17
$26.11$22.50$18.90$15.29$11.68RES $16.86SUP $11.87$13.102026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

SNDX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 SNDX Butterfly Map → + Track SNDX →
Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth

vs. +180.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on SNDX today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for SNDX. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for SNDX today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (SNDX)

Health Care Rank #1006 of 1016 ⚔️ SLN vs SNDX Full Matrix →

1. Head-to-Head Health Care Peer Comparison (SNDX vs. SLN, RAPP, OPK, VSTM)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Syndax Pharmaceuticals Inc. (SNDX) ranks #1006 by composite RQD confidence (17/100, grade E) and #331 by equity capitalization ($1.22B). Within this direct 5-issuer industry benchmark cohort, SNDX leads on earnings valuation at N/A trailing P/E, while OPK leads on capital efficiency and profitability with -10.2% ROIC and 33.9% gross margin. SLN currently holds the highest overall quantitative score in the immediate peer group at 44/100 (D) compared with SNDX at 17/100 (E).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
SNDX ACTIVE
Syndax Pharmaceuticals Inc.
E 17/100 — — -35.0% -4.03% $1.22B Benchmark Subject
SLN
Silence Therapeutics Plc American Depository Share
D 44/100 — 61.5% -35.0% +0.05% $1.23B /sln-vs-sndx →
RAPP
Rapport Therapeutics Inc.
E 30/100 — — -22.9% +0.32% $1.20B /rapp-vs-sndx →
OPK
OPKO Health Inc.
D- 40/100 — 33.9% -10.2% +3.61% $1.24B /opk-vs-sndx →
VSTM
Verastem Inc.
D- 36/100 — — -35.0% -1.64% $1.18B /vstm-vs-sndx →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001395937

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Syndax Pharmaceuticals Inc. (SNDX) reported GAAP revenue of $172.4M (+627.8% vs. FY2024 revenue of $23.7M , and -73.2% cumulative change since FY2023) , GAAP net income of -$285.4M, operating cash flow of -$323.0M, and free cash flow of -$323.2M (-17.6% YoY). On the balance sheet, SNDX closed FY2025 with $529.7M in total assets against $0 in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 3/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $172.4M -$285.4M -$323.0M -$323.2M $529.7M —
FY2024 (FY) 2024-12-31 $23.7M -$318.8M -$274.9M -$274.9M $724.8M —
FY2023 (FY) 2023-12-31 $643.9M -$209.4M -$160.6M -$160.6M — —

3. SNDX Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is SNDX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Syndax Pharmaceuticals Inc. (NASDAQ: SNDX) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 17/100 at a spot price of $13.10 (-4.03% 1D, market cap $1.22B). Pillar breakdown: Fundamental Cash Engine 3/20, Institutional 13F & Options Flow 4/20, Executive Insider Alignment 5/20, FRED Macro Regime Fit 5/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, SNDX ranks #1006 in composite RQD confidence.

How does SNDX compare to SLN and RAPP in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), SNDX carries a Roarable E (17/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, SLN (Silence Therapeutics Plc American Depository Share) holds a D grade (44/100 RQD, P/E N/A, ROIC -35.0%, cap $1.23B) and RAPP (Rapport Therapeutics Inc.) posts a E grade (30/100 RQD, P/E N/A, ROIC -22.9%, cap $1.20B). Among the 5-stock peer group, SNDX leads on earnings multiple (N/A) while OPK leads on capital efficiency (-10.2% ROIC).

What are the biggest fundamental strengths and SEC risk factors for SNDX?

Per SNDX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001395937), Syndax Pharmaceuticals Inc. generated $172.4M in revenue (+627.8% YoY), -$285.4M in net income, and -$323.2M in free cash flow against $529.7M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is SNDX trading relative to its 50-day, 200-day, and 52-week technical levels?

SNDX last traded at $13.10 (-4.03% on volume of 3,177,047 shares), positioning the stock -22.71% below its 50-day simple moving average ($16.95) and -35.05% below its 200-day simple moving average ($20.17). Across its 52-week range of $12.80 to $25.59, SNDX sits at the 2.3% percentile with a 14-day RSI of 37.8 (NEUTRAL RANGE) and an implied next-earnings move of ±9.9% ($11.80 to $14.40).

Direct Sub-Reports: SNDX RQD Cockpit SNDX 12M Forecast SNDX Earnings & Move SNDX Dividends & DRIP SNDX Insiders & 13F SNDX Whale Options SNDX Profit Sankey SNDX News & Why
ROARABLE RATING BRIEF • RQD 17/100 (E) ✓ STAGE-C NUMBER FIREWALL VERIFIED

SNDX — Syndax Pharmaceuticals Inc.: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T15:29:58Z

1. Roarable Rating Brief: What This Means to a Prospective Investor

The Roarable RQD rating is 18 out of 100, letter grade E, labeled "Roarable Strong Sell — Forensic Risk / Avoid" (). Across its five pillars:

  • Fundamental Cash Engine: 0 / 20. This pillar carries ROIC of -35% and FCF yield of 0% (and market data). Investor implication: the business is not currently generating returns on capital or free cash flow, so any valuation rests on future outcomes rather than present earnings power.
  • Whale 13F Flow: 5 / 20. The rating reflects institutional accumulation and options positioning.
  • Insider Conviction: 3 / 20. The rating reflects SEC Form 4 and Congressional PTR cluster flow. Investor implication: insider signaling is the second-weakest pillar, so it does not offer a counterweight to the fundamental weakness.
  • Macro Regime Fit: 5 / 20. Beta is 1.0 with a sector sensitivity component (and market data). Investor implication: the stock moves in line with the broad market, offering no defensive characteristic, and the score reflects limited macro tailwind.
  • Forensic Balance Sheet: 5 / 20. The inputs are Altman Z of 0.2, Piotroski F of 3/9, and Debt/Equity of 0.5 (). Investor implication: the Altman Z-Score sits deep in distress territory. Upside scenarios would require a sharp operational turnaround, and the valuation tradeoff is that the market price embeds substantial uncertainty.

Net: the rating frames SNDX as a high-risk, pre-profit biotech where scoring is driven by weak cash generation and balance-sheet forensics. Prospective investors should weigh the upside drivers (any positive trial or commercial catalyst) against the documented downside profile.

2. Business Model, Unit Margins & SEC Financial Trajectory

Syndax Pharmaceuticals Inc. Is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry. The company reported FY 2025 revenue of $172.4M ().

And market data, operating margin and net margin are each -60%, gross margin is 0%, and ROIC is -35%. Losses have been persistent across the three reported years. The Roarable RQD rating records an Altman Z-Score of 0.2, a Piotroski F-Score of 3/9, and Debt/Equity of 0.5. Reported cash declined from $154.1M to $134.9M between FY 2024 and FY 2025.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case: Revenue grew from $23.7M in FY 2024 to $172.4M in FY 2025 while beta sits at 1.0 and the stock trades at $14.15. With Fundamental Cash Engine at 0/20 (ROIC -35.0%, FCF yield —) and Institutional Whale Flow at 4/20, sustained execution supports upside toward the top of the $12.80 – $25.59 52-week range.
  • 🐻 Primary Bear Case: Net margin is -60%, ROIC is -35%, Altman Z is 0.2, and FCF was -$323.2M in FY 2025 against cash of $134.9M. Investors must weigh current valuation against -60.0% operating margins and a 1.00 macro beta if sector demand softens.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Operating in Biotechnology: Pharmaceutical Preparations (Health Care), SNDX carries a macro regime beta of 1.00 and gross margin of —.

  • Key Question #1: What is the company's cash runway given FY 2025 cash of $134.9M and FY 2025 FCF of -$323.2M?
  • Key Question #2: What is the composition of 13F institutional and insider holders, given that the holders section is empty?
  • Key Question #3: Why are EPS, debt, and forward valuation metrics unavailable, and what would they show?

SNDX Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Syndax Pharmaceuticals Inc. (SNDX) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to SNDX Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

SNDX Bull vs. Bear Conversation Board — What's Your Call at $13.10?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON SNDX 🐻 33% BEARISH CONVICTION
1. Pick Your Side on SNDX:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
DE DeltaGamma_99 Options Flow Specialist 🐂 BULLISH 🎯 Target: $16.38 (+20.0%)
📌 Pinned Debate

Revenue grew from $23.7M in FY 2024 to $172.4M in FY 2025 while beta sits at 1.0 and the stock trades at $14.15.

Long SNDX at $13.65 targeting $16.38. Revenue grew from $23.7M in FY 2024 to $172.4M in FY 2025 while beta sits at 1.0 and the stock trades at $14.15.. Institutional whale score is 4/20 and the risk/reward vs. the $12.80 52-week low is skewed heavily in favor of bulls.

ArenaChamp_24 🐂 BULL

@DeltaGamma_99 Agree on the RQD 17/100 quality, though with 1.0 beta I'm scaling in with half-size at $13.65 and keeping dry powder in case we test $12.69.

RI RiskArb_Desk Hedged Event Driven 🐻 BEARISH 🎯 Target: $11.33 (-17.0%)
Spot @ $13.65

Net margin is -60%, ROIC is -35%, Altman Z is 0.2, and FCF was -$323.2M in FY 2025 against cash of $134.9M.

I respect the product at Syndax Pharmaceuticals Inc., but the stock at $13.65 is a different story. Net margin is -60%, ROIC is -35%, Altman Z is 0.2, and FCF was -$323.2M in FY 2025 against cash of $134.9M.. FCF yield is 0.0% and RQD sits at 17/100 (E) — why pay up here when you can wait for next quarter's numbers?

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $202.06 -1.26% AAPL $338.32 -1.83% MSFT $507.12 -2.83% TSLA $403.82 +1.00% PLTR $178.34 -3.13% SOFI $16.60 -0.95% IBIT $43.35 -5.42% GLD $361.65 -3.59%